By Counterforce Health Team in Pombiliti (cipaglucosidase alfa-atga) —

Getting Pombiliti (Cipaglucosidase Alfa-atga) Covered by Humana in Pennsylvania: Prior Authorization, Appeals, and Cost Assistance

Answer Box: Fastest Path to Coverage

Pombiliti requires prior authorization from Humana and is typically covered as a Part D specialty drug through CenterWell Specialty Pharmacy. Your prescriber must submit a PA request with documented late-onset Pompe disease diagnosis, prior ERT response, and clinical justification. If denied, you have 60-65 days to appeal through Medicare's redetermination process. Start by having your specialist call Humana's PA line at 866-488-5995 to initiate coverage determination.

Table of Contents

  1. What Drives Pombiliti Costs with Humana
  2. Benefit Investigation: Key Questions to Ask
  3. Financial Assistance Options
  4. Prior Authorization Requirements
  5. Specialty Pharmacy and Infusion Settings
  6. Appeals Process for Denials
  7. Annual Renewal and Budget Planning
  8. Scripts for Key Conversations
  9. FAQ: Common Pombiliti Coverage Questions

What Drives Pombiliti Costs with Humana

Pombiliti (cipaglucosidase alfa-atga) costs are influenced by several factors under Humana Medicare plans in Pennsylvania. As a specialty enzyme replacement therapy, Humana requires prior authorization and typically places it on the highest formulary tier with percentage-based coinsurance rather than flat copays.

Coverage Framework

Part D vs Part B Determination: Most Humana Medicare plans treat Pombiliti as a Part D specialty drug when dispensed through specialty pharmacy for outpatient infusion. However, if administered in a hospital outpatient setting where the facility "buys and bills," it may be covered under Part B with different cost-sharing.

Formulary Tier Placement: Research indicates Pombiliti is not listed on Humana's standard 2024/2025 formularies, meaning it requires a formulary exception for coverage. When approved, it's likely assigned specialty-tier cost-sharing of 25-40% coinsurance.

Cost Drivers Table

Cost Factor Impact What You Pay Source
Specialty Tier High coinsurance 25-40% of drug cost Humana Drug Lists
Part D Phases Varies by phase Deductible → Coinsurance → Gap → Catastrophic Medicare Part D structure
Infusion Setting Site-of-care fees Facility fees if outpatient clinic Plan-specific
Prior Auth Required No coverage without approval Humana PA Policy

Benefit Investigation: Key Questions to Ask

Before starting Pombiliti, conduct a thorough benefit investigation with Humana to understand your exact coverage and costs.

Questions for Humana Customer Service

Call the number on your ID card and ask:

  1. Formulary Status: "Is Pombiliti (cipaglucosidase alfa-atga) on my plan's formulary? If not, what's the process for a formulary exception?"
  2. Part Coverage: "Will Pombiliti be covered under Part B or Part D for my plan? How does the infusion setting affect this?"
  3. Cost Estimates: "What will my out-of-pocket cost be for Pombiliti in each Part D benefit phase?"
  4. Specialty Pharmacy: "Must I use CenterWell Specialty Pharmacy? Are there other in-network specialty pharmacies?"
  5. Infusion Options: "Can I receive home infusion through Humana's program, or must I use an infusion center?"

Information to Record

Document these details from your call:

  • Reference number and representative name
  • Exact formulary tier (if covered) or exception process
  • Estimated monthly out-of-pocket costs
  • Required specialty pharmacy
  • Prior authorization timeline
  • Appeal deadlines if denied

Financial Assistance Options

Several programs can help reduce Pombiliti costs, though Medicare beneficiaries have limited options for manufacturer assistance.

Manufacturer Programs

Amicus Assist Copay Program: Available only for commercial insurance, not Medicare beneficiaries. Eligible patients with private insurance may pay as little as $0 per month.

Patient Assistance Program: Amicus offers free medication to qualified uninsured or underinsured patients through their patient assistance program.

Contact: Call 1-833-AMICUS-A (1-833-264-2872), Monday–Friday, 8AM–8PM ET.

Independent Foundation Support

Medicare beneficiaries should explore:

  • Patient Access Network (PAN) Foundation: Provides copay assistance for rare diseases
  • HealthWell Foundation: Offers grants for specialty medications
  • National Organization for Rare Disorders (NORD): Patient assistance programs

State Resources

Pennsylvania residents can access:

  • PA Insurance Department Consumer Services: Help with coverage issues and appeals
  • Medicare SHIP Program: Free counseling for Medicare beneficiaries
  • Pennie Consumer Assistance: For marketplace plans

Prior Authorization Requirements

Humana requires prior authorization for Pombiliti across all plan types. The approval process typically takes up to 7 days for standard requests, with 24-hour expedited review available when delay risks health.

Required Documentation

Your prescriber must submit:

Clinical Evidence:

  • Confirmed late-onset Pompe disease diagnosis
  • Genetic testing or enzyme assay results
  • Current symptoms and functional status
  • Prior enzyme replacement therapy history and response

Treatment Justification:

  • Why Pombiliti is medically necessary
  • Documentation that patient is not improving on current ERT
  • Planned dosing (20 mg/kg IV every 2 weeks)
  • Confirmation of use with Opfolda per FDA labeling

Submission Process

For Medicare Advantage: Providers submit PA requests via:

Timeline: Humana has up to 7 days for standard decisions, 24 hours for expedited requests.

Tip: Request expedited review if any delay in starting Pombiliti would jeopardize your health or ability to regain function.

Specialty Pharmacy and Infusion Settings

Humana typically requires specialty drugs like Pombiliti to be dispensed through CenterWell Specialty Pharmacy, their in-network specialty pharmacy partner.

Infusion Location Options

Outpatient Infusion Centers:

  • Hospital-based outpatient departments
  • Freestanding infusion centers
  • May involve facility fees under Part B

Home Infusion:

  • Humana offers home infusion services for eligible patients
  • Drug dispensed via CenterWell (Part D)
  • Nursing services billed separately (medical benefit)
  • Often more convenient and potentially lower cost

Coordination Steps

  1. Pharmacy Setup: CenterWell will coordinate with your prescriber for PA and benefits verification
  2. Site Selection: Choose between clinic or home infusion based on cost and preference
  3. Scheduling: CenterWell ships medication to your chosen infusion site
  4. Monitoring: Regular coordination between pharmacy, infusion provider, and prescriber
Note: Confirm your chosen infusion center is in-network with your Humana plan to avoid additional out-of-network charges.

Appeals Process for Denials

If Humana denies Pombiliti coverage, you have specific appeal rights under Medicare regulations. Pennsylvania's state external review program does not apply to Medicare Advantage plans, which follow federal Medicare appeal rules.

Medicare Appeals Timeline

Level 1 - Redetermination:

  • File within 60-65 days of denial
  • Humana reviews the decision
  • Timeline: Up to 7 days for Part D drugs

Level 2 - Reconsideration:

  • Independent Review Entity (IRE) reviews if Level 1 upheld
  • Must file within 60 days of redetermination
  • Timeline: 7 days standard, 72 hours expedited

Appeal Documentation

Strengthen your appeal with:

  • Updated clinical notes showing disease progression
  • Peer-reviewed literature supporting Pombiliti use
  • Specialist letter addressing specific denial reasons
  • Documentation of prior ERT failures or inadequate response

Counterforce Health Support

Counterforce Health specializes in turning insurance denials into targeted appeals for specialty medications. Their platform analyzes denial letters and plan policies to create evidence-backed rebuttals that address specific payer criteria, potentially improving your appeal success rate.

When to Consider: If your initial appeal is denied or if the denial involves complex medical necessity arguments requiring extensive clinical evidence.

Annual Renewal and Budget Planning

Humana can modify formularies, prior authorization requirements, and cost-sharing annually. Plan ahead for potential changes.

Annual Review Checklist

October-December (Open Enrollment):

  • Review next year's formulary for Pombiliti placement
  • Compare cost-sharing changes
  • Evaluate plan alternatives if coverage worsens

January (Plan Year Start):

  • Confirm continued PA approval
  • Update any changed pharmacy or provider networks
  • Budget for new deductible phase

Budget Considerations

  • Deductible Phase: Full specialty-tier cost until deductible met
  • Coverage Gap: Potential higher costs in "donut hole"
  • Catastrophic Phase: Lower costs after True Out-of-Pocket (TrOOP) threshold
  • Premium Changes: Factor in monthly premium adjustments

Scripts for Key Conversations

Calling Humana Customer Service

"Hi, I'm calling about coverage for Pombiliti, spelled P-O-M-B-I-L-I-T-I, for late-onset Pompe disease. My member ID is [ID number]. I need to understand the prior authorization requirements, which specialty pharmacy I must use, and my estimated out-of-pocket costs. Can you also tell me if this would be covered under Part B or Part D?"

Prescriber Office PA Request

"We need to submit a prior authorization for Pombiliti for our patient with late-onset Pompe disease. Please include the genetic testing confirming GAA deficiency, documentation of inadequate response to [previous ERT], current functional status including pulmonary function tests, and confirmation that we're prescribing per FDA labeling with Opfolda. The patient is requesting expedited review due to disease progression."

Appeal Letter Opening

"I am writing to appeal the denial of coverage for Pombiliti (cipaglucosidase alfa-atga) for [patient name], member ID [number]. This medication is FDA-approved and medically necessary for my patient's late-onset Pompe disease based on inadequate response to prior enzyme replacement therapy and documented disease progression."

FAQ: Common Pombiliti Coverage Questions

Q: How long does Humana prior authorization take for Pombiliti in Pennsylvania? A: Standard PA decisions take up to 7 days. Expedited requests are decided within 24 hours when delay would jeopardize health.

Q: What if Pombiliti is non-formulary on my Humana plan? A: You can request a formulary exception. Your prescriber must demonstrate medical necessity and why formulary alternatives are inadequate.

Q: Can I use manufacturer copay assistance with Humana Medicare? A: No, Amicus copay assistance is not valid for Medicare beneficiaries. Explore the patient assistance program or independent foundations instead.

Q: Does step therapy apply to Pombiliti? A: Possibly. Humana may require trial and failure of other ERTs like Lumizyme or Nexviazyme before approving Pombiliti, unless contraindicated.

Q: Can I appeal to Pennsylvania's external review program? A: No, Pennsylvania's external review program doesn't cover Medicare Advantage plans. Use Medicare's federal appeal process instead.

Q: What's the difference between home infusion and clinic infusion costs? A: Home infusion through Humana's program may have lower facility fees but separate nursing charges. Get cost estimates for both settings.

Q: How often do I need to renew Pombiliti prior authorization? A: This varies by plan. Some require annual renewal, others approve for longer periods. Check with Humana and mark your calendar for reauthorization deadlines.

Q: What happens if I travel outside Pennsylvania? A: Humana Medicare Advantage plans typically provide coverage nationwide for urgent/emergent care, but routine infusions should be coordinated through your plan's network.

Counterforce Health helps patients and clinicians navigate complex prior authorization requirements for specialty medications like Pombiliti. By analyzing plan policies and denial patterns, Counterforce Health creates targeted appeals that address specific payer criteria, improving approval rates for medically necessary treatments.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and can change. Always verify current requirements with Humana and consult your healthcare provider for medical decisions. For personalized assistance with coverage issues, contact the Pennsylvania Insurance Department's Bureau of Consumer Services or Medicare's SHIP program.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.